PMID: 9184724Jun 1, 1997Paper

Riluzole--what is its impact in our treatment and understanding of amyotrophic lateral sclerosis?

The Annals of Pharmacotherapy
H Mitsumoto

Abstract

Riluzole marks the beginning of pharmacotherapy for patients with ALS. Our task is to fully identify the impact of riluzole in ALS treatment. The ALS Clinical Assessment Research and Education (ALS CARE) is an ambitious database in North America created to establish the benchmarks for patient care and management. Such a program may allow us to analyze the use and impact of riluzole in the treatment of ALS. In the spring of 1997, just 1 year since the approval of riluzole, several more potential drugs for ALS are on the horizon. If a single medication is not sufficient to alter the disease course significantly, we must investigate drug combinations to determine potential additive or synergistic benefits. Although far from ideal, riluzole is allowing clinicians and researchers to lift a corner of the veil surrounding ALS to glimpse the possibility of effective treatment.

References

Jul 1, 1995·Annals of Neurology·J D RothsteinR W Kuncl
Mar 1, 1995·Journal of the Neurological Sciences·T C Guthrie, D A Nelson
Mar 3, 1994·The New England Journal of Medicine·G BensimonV Meininger
Oct 1, 1996·Neurology·J D Rothstein
Oct 1, 1996·Neurology·F A Anderson, R G Miller
Jun 1, 1997·The Annals of Pharmacotherapy·M L Wagner, B E Landis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.